Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EPS (Weighted Average and Diluted) (2020 - 2025)

Ovid Therapeutics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at $141.83 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 210.7% year-over-year to $141.83; the TTM value through Dec 2025 reached -$91.05, up 29.07%, while the annual FY2025 figure was -$232.47, 36.54% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $141.83 in Q4 2025 per OVID's latest filing, up from -$168.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $141.83 in Q4 2025 to a low of -$728.12 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$47.35, with a median of -$0.18 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 783.78% in 2021, then tumbled 454975.0% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.38 in 2021, then soared by 57.89% to -$0.16 in 2022, then crashed by 454975.0% to -$728.12 in 2023, then soared by 82.4% to -$128.12 in 2024, then skyrocketed by 210.7% to $141.83 in 2025.
  • Per Business Quant, the three most recent readings for OVID's EPS (Weighted Average and Diluted) are $141.83 (Q4 2025), -$168.01 (Q3 2025), and -$64.73 (Q2 2025).